Muscle Loss on GLP-1s: What the Research Shows and How to Protect Lean Mass
What current research shows about lean-mass loss during GLP-1 weight loss, and evidence-informed ways to protect muscle.
Do GLP-1 medications cause muscle loss?
Some of the weight lost on GLP-1 medications is lean mass, as with most substantial weight loss. Research suggests a meaningful share of total weight lost can come from fat-free mass, which is why protein intake and resistance exercise are commonly recommended alongside treatment. Discuss a plan with your clinician.
Disclaimer: American Telehealth Review is an editorial resource and does not provide medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved finished drug products and should only be prescribed when clinically appropriate by a licensed healthcare provider. Brand-name medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are FDA-approved under their own applications. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products.
What the evidence indicates
Rapid weight loss of any kind reduces both fat and lean mass. Trials and analyses of GLP-1 therapy show lean-mass changes, and research into muscle-preserving strategies and adjunct agents is ongoing. The clinical priority is preserving function and strength.
Evidence-informed protection
Adequate protein intake, resistance training, and gradual, supervised titration are widely recommended to protect lean mass during GLP-1 weight loss. A provider that includes coaching and follow-up supports this.
Frequently asked questions
Is muscle loss on GLP-1s avoidable?
Some lean-mass loss accompanies major weight loss, but protein intake and resistance exercise help preserve muscle. Discuss with your clinician.
Should I lift weights on a GLP-1?
Resistance training is commonly recommended to help protect lean mass during weight loss; follow personalized medical advice.
Sources
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022.
- U.S. FDA — Medications containing semaglutide and tirzepatide; Compounding and the FDA (fda.gov).